Nom du produit:3-Methyl-2-(methylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-4(3H)-one
IUPAC Name:3-methyl-2-(methylsulfanyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydropyrimidin-4-one
- CAS：1628606-29-0
- Formule moléculaire：C12H19BN2O3S
- Pureté：97%
- Numéro de catalogue：CM210800
- Poids moléculaire：282.17
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1628606-29-0
- Formule moléculaire:C12H19BN2O3S
- Point de fusion:-
- Code SMILES:O=C1C(B2OC(C)(C)C(C)(C)O2)=CN=C(SC)N1C
- Densité:
- Numéro de catalogue:CM210800
- Poids moléculaire:282.17
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Pyrimidines
- Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
- Boronic Acids and Esters
- Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
- Boronic Acid For Sale
- Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.
Column Infos
- Vimseltinib
- Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.
Recherche 
+86 21 5895 0110 
